The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Yonesaka, Kimio, Kudo, Keita, Nishida, Satomi, Takahama, Takayuki, Iwasa, Tsutomu, Yoshida, Takeshi, Tanaka, Kaoru, Takeda, Masayuki, Kaneda, Hiroyasu, Okamoto, Isamu, Nishio, Kazuto, Nakagawa, Kazuhiko
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741788/
https://ncbi.nlm.nih.gov/pubmed/26418897
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi